Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
REGN News
Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...
Regeneron Pharmaceuticals, Inc. REGN announced updated data on its investigational gene therapy DB-OTO from the CHORD study. This gene therapy is being evaluat...
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Analyst ratings
76%
of 29 ratingsMore REGN News
Regeneron (REGN) Pharmaceuticals announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society f...
Bank of America Securities analyst Tim Anderson reiterated a Sell rating on Regeneron today and set a price target of $543.00. Elevate Your Investing Strategy:...
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. ( REGN ) is a biotechnology company that invents, develops, manufactures, and commercializes medicines...
On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss ca...
Novo Nordisk’s (NVO) update that the FDA classified Catalent’s facility as “Official Action Indicated” raises the risk of further delay for Regeneron’s (REGN) E...
Citi analyst Geoff Meacham raised the firm’s price target on Regeneron (REGN) to $660 from $650 and keeps a Buy rating on the shares. The firm adjusted price ta...
Regeneron Pharmaceuticals recently announced that the U.S. FDA approved Libtayo (cemiplimab-rwlc) as the first immunotherapy for adjuvant treatment of adult pat...
